Clinical Trial Update: Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing orelabrutinib in combination with rituximab, followed by orelabrutinib maintenance, for relapsed and refractory follicular lymphoma. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma | Phase 2 | Status: RECRUITING